Literature DB >> 11329820

The treatment of hypertension in patients with erectile dysfunction.

D P Mikhailidis1, M A Khan, H J Milionis, R J Morgan.   

Abstract

Hypertension is another predictor of erectile dysfunction (ED). This is further evidence supporting a link between the pathogenesis of atherosclerotic disease and ED. In one study (TOMHS) involving hypertensive patients, the incidence of ED was 14.4%. The drugs used to treat hypertension may cause ED. However, there is little trial-based evidence to indicate which drugs are more likely to cause this side effect. In general, thiazide diuretics and beta-blockers seem to cause ED more often. In contrast, the alpha-blocker, doxazosin, has not been associated with an increased incidence of ED as a side effect. Doxazosin also improves urinary flow in patients with benign prostatic hyperplasia (BPH). This condition is common in elderly men as is hypertension and ED. Therefore, doxazosin may present a special advantage among this group of patients. This alpha-blocker would also be a good choice in patients with impaired glucose tolerance/diabetes because it improves insulin sensitivity. Moreover, ED and hypertension are more prevalent among diabetics. On a more speculative note, doxazosin may potentiate the therapeutic impact of specific treatments for ED.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11329820     DOI: 10.1185/0300799009117037

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  7 in total

Review 1.  Treatment of benign prostatic hyperplasia in patients with cardiovascular disease.

Authors:  Vincent M Santillo; Franklin C Lowe
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

2.  Prevalence and risk factors of erectile dysfunction in Niger delta region, Nigeria.

Authors:  A U Idung; F Abasiubong; I A Ukott; S B Udoh; B C Unadike
Journal:  Afr Health Sci       Date:  2012-06       Impact factor: 0.927

3.  Managing erectile dysfunction in hypertensive patients.

Authors:  Joel Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-04-22       Impact factor: 3.738

Review 4.  Erectile dysfunction: symptom or disease?

Authors:  C Foresta; N Caretta; A Aversa; C Bettocchi; G Corona; S Mariani; M Rossato
Journal:  J Endocrinol Invest       Date:  2004-01       Impact factor: 4.256

Review 5.  Future options for combination therapy in the management of erectile dysfunction in older men.

Authors:  Frank Sommer; Udo Engelmann
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 6.  Erectile dysfunction: expectations beyond phosphodiesterase type 5 inhibition.

Authors:  A Aversa; M Pili; A Fabbri; E Spera; G Spera
Journal:  J Endocrinol Invest       Date:  2004-02       Impact factor: 4.256

7.  Erectile dysfunction in patients with liver disease related to chronic hepatitis B.

Authors:  Min Kim; Seul Young Kim; Woo Sun Rou; Se Woong Hwang; Byung Seok Lee
Journal:  Clin Mol Hepatol       Date:  2015-12-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.